A share price of Phathom Pharmaceuticals Inc [PHAT] is currently trading at $6.23, down -0.48%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The PHAT shares have gain 41.27% over the last week, with a monthly amount glided 12.45%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Phathom Pharmaceuticals Inc [NASDAQ: PHAT] stock has seen the most recent analyst activity on February 14, 2025, when Cantor Fitzgerald initiated its Overweight rating and assigned the stock a price target of $23. Previously, Stifel started tracking the stock with Buy rating on May 03, 2024, and set its price target to $24. On January 05, 2024, Needham reiterated its Buy rating and revised its price target to $26 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $28 on August 09, 2023. Evercore ISI upgraded its rating to a Outperform. Craig Hallum started tracking with a Buy rating for this stock on March 13, 2023, and assigned it a price target of $21. In a note dated October 21, 2022, Jefferies initiated an Buy rating and provided a target price of $16 on this stock.
Phathom Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $4.07 and $19.71. Currently, Wall Street analysts expect the stock to reach $18 within the next 12 months. Phathom Pharmaceuticals Inc [NASDAQ: PHAT] shares were valued at $6.23 at the most recent close of the market. An investor can expect a potential return of 188.92% based on the average PHAT price forecast.
Analyzing the PHAT fundamentals
Trailing Twelve Months sales for Phathom Pharmaceuticals Inc [NASDAQ:PHAT] were 55.25M which represents 4249.56% growth. Gross Profit Margin for this corporation currently stands at 0.86% with Operating Profit Margin at -5.02%, Pretax Profit Margin comes in at -6.05%, and Net Profit Margin reading is -6.05%. To continue investigating profitability, this company’s Return on Assets is posted at -0.88, Equity is 1.62 and Total Capital is -0.95. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.8.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 6.01 points at the first support level, and at 5.80 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.49, and for the 2nd resistance point, it is at 6.76.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Phathom Pharmaceuticals Inc [NASDAQ:PHAT] is 4.20. As well, the Quick Ratio is 4.16, while the Cash Ratio is 3.47. Considering the valuation of this stock, the price to sales ratio is 7.85.
Transactions by insiders
Recent insider trading involved Parikh Asit, Director, that happened on Mar 13 ’25 when 10000.0 shares were purchased. CFO and CBO, Henderson Molly completed a deal on Jan 21 ’25 to sell 6583.0 shares. Meanwhile, Chief Operating Officer Nabulsi Azmi sold 7886.0 shares on Jan 21 ’25.
